High intensity focused ultrasound (HIFU)
- PMID: 21504653
High intensity focused ultrasound (HIFU)
Abstract
Introduction: Curative treatments for localized prostate cancer, from least invasive to most invasive, include brachytherapy, cryosurgery, three-dimensional conformal radiation therapy, external beam radiation therapy, and radical prostatectomy. A patient with localized, low risk or intermediate risk prostate cancer who is diagnosed at an early age and receives one of these treatments has only an approximately 50% chance of maintaining an undetectable prostate-specific antigen (PSA) level, good spontaneous erections, and total continence by 5 years after treatment.
Objective: This article discusses transrectal high intensity focused ultrasound (HIFU) treatment of localized prostate cancer using the Sonablate 500 (Focus Surgery, Indianapolis, IN, USA) device, which the author has adopted in favor of the Ablatherm (EDAP, TMS S. A., Lyons, France) device, the other HIFU device approved for use in Canada.
Method: Characteristics of the ideal prostate cancer include stage T1-T2b, less than 40 cc in size, and with an anterior-posterior dimension of up to 35 mm high. The anterior zone of the prostate is treated before the posterior zone. The procedure involves 2 to 3 second bursts of ultrasound energy, followed by 3 second cooling cycles. In each treatment lesion, the physician achieves a temperature of 100 C at the focal point. The device allows for real-time visualization of tissue response following the delivery of ultrasound energy.
Conclusion: HIFU is a minimally invasive, outpatient treatment for localized prostate cancer that provides similar short term and medium term cure rates and considerably less morbidity and side effects than other treatments. Although the effectiveness of HIFU has not yet been demonstrated in large, long term studies, this treatment option should be discussed with patients who have just been diagnosed with low risk or intermediate risk prostate cancer and desire aggressive, noninvasive, curative therapy, with potentially a lower incidence of side effects compared to conventional therapy.
Similar articles
-
Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.BJU Int. 2012 Dec;110(11):1702-7. doi: 10.1111/j.1464-410X.2012.11375.x. Epub 2012 Aug 29. BJU Int. 2012. PMID: 22928703
-
Results of high intensity focused ultrasound treatment of prostate cancer: early Canadian experience at a single center.Can J Urol. 2011 Dec;18(6):6037-42. Can J Urol. 2011. PMID: 22166332
-
High Intensity Focused Ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results.Acta Biomed. 2008 Dec;79(3):211-6. Acta Biomed. 2008. PMID: 19260381
-
High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience.Urology. 2004 Feb;63(2):297-300. doi: 10.1016/j.urology.2003.09.020. Urology. 2004. PMID: 14972475 Review.
-
High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer.BJU Int. 2012 Nov;110(9):1228-42. doi: 10.1111/j.1464-410X.2012.11262.x. Epub 2012 Jun 6. BJU Int. 2012. PMID: 22672199 Review.
Cited by
-
High-Intensity Focused Ultrasound (HIFU) in Localized Prostate Cancer Treatment.Pol J Radiol. 2015 Mar 13;80:131-41. doi: 10.12659/PJR.892341. eCollection 2015. Pol J Radiol. 2015. PMID: 25806099 Free PMC article. Review.
-
Focal therapy for localized prostate cancer - Current status.Indian J Urol. 2022 Jan-Mar;38(1):7-14. doi: 10.4103/iju.iju_166_21. Epub 2022 Jan 1. Indian J Urol. 2022. PMID: 35136289 Free PMC article. Review.
-
Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications.Cancer Manag Res. 2022 Mar 22;14:1209-1228. doi: 10.2147/CMAR.S265058. eCollection 2022. Cancer Manag Res. 2022. PMID: 35345605 Free PMC article. Review.
-
Super active surveillance for low-risk prostate cancer | Opinion: No.Int Braz J Urol. 2019 Mar-Apr;45(2):215-219. doi: 10.1590/S1677-5538.IBJU.2019.02.03. Int Braz J Urol. 2019. PMID: 31021585 Free PMC article. No abstract available.
-
Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies.Drug Deliv Transl Res. 2021 Dec;11(6):2394-2413. doi: 10.1007/s13346-021-01018-0. Epub 2021 Jun 26. Drug Deliv Transl Res. 2021. PMID: 34176099 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous